Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled Drug's heart effects scrutinized in small safety trial

NCT ID NCT00874237

Knowledge-focused Sponsor: Nova Pneuma Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested whether a single inhaled dose of Staccato Loxapine affects the heart's electrical activity in 48 healthy adults. Participants received the drug, a placebo, and a control drug in random order, and their heart rhythms were measured. The goal was to check for heart-related side effects, not to treat any disease. The study found no major heart risks at the tested dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

48 people

The number who actually took part.

Start date

Apr 2009

Finished

Jun 2009

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects who are in good general health and agree to use a medically acceptable and effective birth control method throughout the study. Exclusion Criteria: * Subjects who have taken prescription or nonprescription medication within 5 days of treatment, * Subjects who have had an acute illness within the last 5 days of treatment, * Subjects who are smokers, OR * Subjects who have an ECG abnormality at baseline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thorough QT/QTC study are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thorough QT/QTC study

Contacts and locations

Locations

  • Covance Clinical Research Unit Inc.

    Evansville, Indiana, 47710, United States